Immunotherapy combination increases overall survival in people with kidney cancer, study shows – News-Medical.net
News-Medical.net |
Immunotherapy combination increases overall survival in people with kidney cancer, study shows
News-Medical.net Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according to … |
